Ecto-NTPDase-Inhibitors
Inhibitors for use in human therapy Invention
The invention provides a new class of nucleosides exhibiting a high affinity for individual ecto-nucleotidetriphosphate-diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors).
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Making diamonds at ambient pressure
Scientists develop novel liquid metal alloy system to synthesize diamond under moderate conditions. Did you know that 99% of synthetic diamonds are currently produced using high-pressure and high-temperature (HPHT) methods?[2]…
Eruption of mega-magnetic star lights up nearby galaxy
Thanks to ESA satellites, an international team including UNIGE researchers has detected a giant eruption coming from a magnetar, an extremely magnetic neutron star. While ESA’s satellite INTEGRAL was observing…
Solving the riddle of the sphingolipids in coronary artery disease
Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…